60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity
30 août 2023 07h32 HE
|
Sixty Degrees Pharmaceuticals
Data showed tafenoquine does not exhibit cross-susceptibility with fluconazole against Candida spp.Effective treatment of drug-resistant Candida infections is an unmet need in U.S. marketPresumed mode...
Eye Inflammation Treatment Market to Surpass US$ 888.5 Million by 2030, Says Coherent Market Insights (CMI)
02 mars 2023 09h30 HE
|
CMI
Burlingame, March 02, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global eye inflammation treatment market is estimated to be valued at US$ 564.4 Million in 2022 and is...
Antifungal Drugs Market Report will Surpass USD 25.04 Billion by 2030 at a CAGR of 4.2% Till 2030 : GreyViews
10 févr. 2023 14h00 HE
|
GreyViews
Pune India, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Antifungal Drugs Market Size By Drug Class (Allylamines, Azoles, Polyenes, Echinocandins, and Others), By Route of Administration (Parenteral, Oral and...
Antifungal Drug Market Report Up to 2031: Visiongain Research Inc
05 janv. 2022 09h34 HE
|
Visiongain Ltd
Visiongain has published a new report on Antifungal Drugs Market Report to 2031. Market is segmented by type (Azoles, Echinocandins, Polyenes), By Application (Aspergillosis, Dermatophytosis,...
Cidara Provides Corporate Update and Reports Second Quarter 2019 Financial Results
08 août 2019 16h07 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported financial...
Cidara Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
07 août 2019 07h30 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...
Cidara Therapeutics Reports Positive Topline Results in Phase 2 STRIVE B Trial of Antifungal Rezafungin
29 juil. 2019 07h00 HE
|
Cidara Therapeutics, Inc.
Data from second part of successful Phase 2 STRIVE trial further substantiate the efficacy, safety and tolerability of once-weekly rezafungin for first-line treatment of invasive Candida infections ...
Cidara Provides Corporate Update and Reports First Quarter 2019 Financial Results
09 mai 2019 16h13 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, May 09, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
Cidara Therapeutics to Present at the 18th Annual Needham Healthcare Conference
03 avr. 2019 16h04 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, April 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results
28 févr. 2019 16h24 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...